BCM
PRQR icon

Bayesian Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Bayesian Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,400
Closed -$10K – 985
2022
Q3 		$10K Buy
13,400
+200
+2% +$161 ﹤0.01% 652
2022
Q2 		$10K Sell
13,200
-400
-3% -$298 ﹤0.01% 741
2022
Q1 		$12K Buy
+13,600
New +$45.6K ﹤0.01% 751

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bayesian Capital Management's PRQR Position: Q4 2022 in Review

Bayesian Capital Management sold out of ProQR Therapeutics (PRQR) in Q4 2022, closing a stake of 13,400 shares — an estimated $10K sold.

Bayesian Capital Management first reported a position in PRQR in Q1 2022 and held it in 3 quarters. The position peaked at $12K in Q1 2022. 46 funds tracked by Wall St. Rank hold PRQR as of Q4 2022.

  • Bayesian Capital Management reported no remaining ProQR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 13,400 ProQR Therapeutics shares in Q4 2022, an estimated $10K.
  • Bayesian Capital Management first reported a position in ProQR Therapeutics in Q1 2022 and held it in 3 quarters.
  • Bayesian Capital Management's ProQR Therapeutics position peaked at $12K in Q1 2022.
  • 46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2022.

Based on Bayesian Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.